
  
    
      
        Background_NNP
        Nonadherence_NNP to_TO drug_NN therapy_NN can_MD undermine_VB the_DT
        attainment_NN of_IN therapeutic_JJ goals_NNS and_CC contribute_VB to_TO the_DT
        occurrence_NN of_IN medication_NN side_NN effects_NNS ._. Numerous_JJ adverse_JJ
        clinical_JJ outcomes_NNS have_VBP been_VBN linked_VBN to_TO nonadherence_NN
        including_VBG loss_NN of_IN blood_NN pressure_NN control_NN [_NN 1_CD 2_CD ]_NN ,_, acute_JJ
        cardiac_JJ events_NNS [_NN 3_CD ]_NN ,_, renal_JJ transplant_NN rejection_NN [_NN 4_CD ]_NN ,_,
        seizures_NNS [_NN 5_CD ]_NN ,_, and_CC elevated_VBD Human_NNP Immunodeficiency_NNP Virus_NNP
        RNA_NNP levels_NNS [_NN 6_CD ]_NN ._. Efforts_NNS to_TO enhance_VB medicinal_NN adherence_NN
        have_VBP met_VBN with_IN varying_VBG levels_NNS of_IN success_NN [_NN 7_CD 8_CD 9_CD ]_NN ._.
        The_DT detection_NN of_IN nonadherence_NN to_TO recommended_VBD treatment_NN
        can_MD be_VB problematic_JJ ._. In_IN the_DT clinical_JJ setting_NN asking_VBG patients_NNS
        about_IN their_PRP$ medication_NN use_NN is_VBZ the_DT most_RBS practical_JJ means_NNS of_IN
        ascertainment_NN ,_, but_CC it_PRP is_VBZ prone_JJ to_TO inaccuracy_NN [_NN 10_CD 11_CD ]_NN ._.
        Strategies_NNS to_TO increase_VB the_DT accuracy_NN of_IN screening_NN for_IN
        nonadherence_NN such_JJ as_IN considering_VBG as_IN nonadherent_NN all_PDT those_DT
        who_WP do_VBP not_RB respond_VB to_TO therapy_NN can_MD augment_VB sensitivity_NN ._.
        However_RB ,_, this_DT unfairly_RB mislabels_NNS some_DT adherent_NN patients_NNS as_IN
        nonadherent_NN [_NN 10_CD ]_NN ._. In_IN general_JJ ,_, patients_NNS tend_VBP to_TO
        overestimate_NN their_PRP$ adherence_NN [_NN 8_CD 12_CD ]_NN and_CC unless_IN a_DT patient_NN
        is_VBZ not_RB responding_VBG to_TO therapy_NN ,_, it_PRP may_MD be_VB extremely_RB difficult_JJ
        to_TO identify_VB under-adherence_JJ ._. In_IN research_NN settings_NNS ,_, pill_NN
        counts_VBZ ,_, drug_NN levels_NNS ,_, pharmacy_NN dispensing_VBG records_NNS and_CC
        electronic_JJ medication_NN monitors_NNS are_VBP available_JJ to_TO measure_VB
        medicinal_NN adherence_NN but_CC even_RB some_DT of_IN these_DT methods_NNS such_JJ as_IN
        pill_NN counts_VBZ may_MD be_VB susceptible_JJ to_TO overestimating_VBG adherence_NN
        [_NN 8_CD 13_CD 14_CD 15_CD ]_NN ._. In_IN many_JJ non-research_JJ situations_NNS these_DT
        approaches_NNS may_MD be_VB difficult_JJ to_TO implement_VB due_JJ to_TO their_PRP$
        obtrusiveness_NNS ,_, cost_NN ,_, or_CC complexity_NN ._.
        Although_IN studies_NNS have_VBP been_VBN conducted_VBN to_TO identify_VB risk_NN
        factors_NNS for_IN nonadherence_NN itself_PRP [_NN 16_CD ]_NN ,_, to_TO the_DT best_JJS of_IN our_PRP$
        knowledge_NN ,_, only_RB one_CD previous_JJ study_NN has_VBZ examined_VBN possible_JJ
        risk_NN factors_NNS for_IN 
        over-reporting_JJ of_IN adherence_NN [_NN 17_CD ]_NN ._.
        None_NN has_VBZ utilized_JJ electronic_JJ medication_NN monitors_VBZ to_TO study_VB
        this_DT area_NN involving_VBG antihypertensive_JJ medications_NNS ._. We_PRP
        consequently_RB undertook_VBD this_DT present_JJ study_NN among_IN several_JJ
        hundred_CD individuals_NNS who_WP were_VBD receiving_VBG antihypertensive_JJ
        therapy_NN in_IN order_NN to_TO explore_VB which_WDT demographic_JJ ,_, behavioral_JJ ,_,
        and_CC clinical_JJ characteristics_NNS might_MD be_VB associated_VBN with_IN
        over-reporting_JJ of_IN adherence_NN ._. The_DT investigation_NN was_VBD
        exploratory_JJ in_IN nature_NN and_CC was_VBD meant_VBN to_TO identify_VB possible_JJ
        leads_NNS for_IN future_JJ research_NN ._. Electronic_JJ medication_NN monitors_NNS
        were_VBD used_VBN to_TO track_VB actual_JJ medication_NN use_NN against_IN which_WDT the_DT
        accuracy_NN of_IN patient-reported_JJ adherence_NN was_VBD determined_VBN ._.
      
      
        Methods_NNP
        
          Study_NN population_NN
          The_DT study_NN design_NN of_IN this_DT investigation_NN has_VBZ been_VBN
          described_VBN previously_RB in_IN detail_NN [_NN 15_CD ]_NN ._. Briefly_NNP ,_, the_DT
          study_NN was_VBD conducted_VBN at_IN Harvard_NNP Pilgrim_NNP Health_NNP Care_NNP
          (_( HPHC_NNP )_) ,_, a_DT managed_VBN care_NN organization_NN located_VBN in_IN New_NNP
          England_NNP ,_, among_IN members_NNS who_WP were_VBD receiving_VBG
          antihypertensive_JJ medication_NN from_IN 1992_CD to_TO 1994_CD ._. Automated_NNP
          medical_JJ ,_, pharmacy_NN ,_, and_CC claims_NNS records_NNS of_IN the_DT study_NN
          population_NN were_VBD screened_VBD to_TO identify_VB potential_JJ study_NN
          subjects_NNS and_CC retrieve_VB their_PRP$ outpatient_NN blood_NN pressure_NN
          data_NNS ._. Patients_NNS were_VBD eligible_JJ if_IN they_PRP had_VBD been_VBN HPHC_NNP
          members_NNS for_IN at_IN least_JJS three_CD months_NNS ,_, were_VBD at_IN least_JJS 18_CD years_NNS
          of_IN age_NN ,_, and_CC carried_VBD a_DT diagnosis_NN of_IN hypertension_NN ._. Only_RB
          individuals_NNS on_IN single-drug_JJ therapy_NN for_IN high_JJ blood_NN
          pressure_NN were_VBD selected_VBN to_TO simplify_VB electronic_JJ adherence_NN
          monitoring_NN ._.
          Of_IN 1_CD ,_, 285_CD potentially_RB eligible_JJ individuals_NNS ,_, 330_CD
          consented_VBD to_TO participate_VB and_CC completed_VBD all_DT phases_NNS of_IN the_DT
          study_NN ._. The_DT majority_NN of_IN those_DT who_WP did_VBD not_RB enroll_VB in_IN the_DT
          study_NN (_( 71_CD %_NN )_) declined_VBD mailed_VBN or_CC telephone_NN invitations_NNS to_TO
          participate_VB ._. In_IN addition_NN ,_, 42_CD subjects_NNS dropped_VBD out_IN midway_NN
          through_IN the_DT study_NN ,_, and_CC 44_CD individuals_NNS were_VBD later_RB excluded_VBN
          because_IN of_IN indications_NNS of_IN improper_JJ use_NN of_IN their_PRP$
          electronic_JJ medication_NN monitor_NN such_JJ as_IN removal_NN of_IN multiple_JJ
          doses_NNS at_IN an_DT opening_NN or_CC incomplete_JJ closure_NN of_IN the_DT
          medication_NN vial_NN ._. The_DT remaining_VBG 286_CD patients_NNS constituted_VBD
          the_DT study_NN population_NN for_IN this_DT investigation_NN ._. Individuals_NNS
          who_WP were_VBD eligible_JJ but_CC did_VBD not_RB complete_VB this_DT investigation_NN
          had_VBD a_DT similar_JJ age_NN ,_, gender_NN ,_, and_CC blood_NN pressure_NN
          distribution_NN as_IN our_PRP$ study_NN population_NN ._. However_RB ,_, calcium_NN
          antagonists_NNS were_VBD prescribed_VBN slightly_RB more_RBR frequently_RB (_( 37_CD %_NN
          versus_CC 24_CD %_NN )_) and_CC angiotensin-converting_JJ inhibitors_NNS less_RBR
          frequently_RB (_( 37_CD %_NN versus_CC 49_CD %_NN )_) to_TO individuals_NNS excluded_VBN from_IN
          the_DT final_JJ study_NN population_NN [_NN 15_CD ]_NN ._.
        
        
          Collection_NNP of_IN electronic_JJ and_CC patient-reported_JJ
          adherence_NN data_NNS
          Individuals_NNS who_WP consented_VBD to_TO participate_VB were_VBD mailed_VBN a_DT
          baseline_NN questionnaire_NN that_WDT covered_VBD their_PRP$ socioeconomic_JJ
          background_NN ,_, medications_NNS (_( antihypertensive_JJ and_CC other_JJ
          drugs_NNS )_) ,_, adherence_NN ,_, health_NN beliefs_NNS ,_, health_NN status_NN (_( Medical_NNP
          Outcomes_NNP Study_NNP ,_, Short_JJ Form_NN [_NN SF-_NNP 36_CD ]_NN )_) [_NN 18_CD ]_NN ,_, and_CC social_JJ
          support_NN ._. Responses_NNS to_TO the_DT questionnaire_NN were_VBD obtained_VBN by_IN
          telephone_NN interview_NN conducted_VBN by_IN a_DT research_NN
          assistant_NN ._.
          Self-reported_NNP adherence_NN during_IN the_DT monitoring_VBG period_NN
          was_VBD obtained_VBN using_VBG the_DT following_NN question_NN ,_, which_WDT was_VBD
          adapted_VBN from_IN the_DT Brief_NNP Medication_NNP Questionnaire_NNP (_( Svarstad_NNP
          B_NNP ._. ,_, personal_JJ communication_NN )_) :_: 
          While_IN you_PRP were_VBD using_VBG the_DT special_JJ
          medication_NN bottle_NN ,_, on_IN how_WRB many_JJ days_NNS in_IN an_DT AVERAGE_NNP WEEK_NNP
          did_VBD you_PRP forget_VBP to_TO take_VB a_DT pill_NN ?_. 0_CD ,_, 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, or_CC 5_CD +_NN
          days_NNS ._. Our_PRP$ previous_JJ study_NN [_NN 15_CD ]_NN had_VBD indicated_VBN that_IN
          responses_NNS to_TO this_DT item_NN (_( compared_VBN with_IN 4_CD other_JJ adherence_NN
          items_NNS )_) correlated_JJ most_RBS closely_RB with_IN adherence_NN as_IN measured_VBN
          by_IN electronic_JJ medication_NN monitoring_NN ._.
          Social_JJ support_NN was_VBD assessed_VBN using_VBG a_DT 9_CD -_: item_NN inventory_NN ._.
          The_DT inventory_NN inquired_VBD about_IN how_WRB often_RB the_DT participant_NN
          could_MD rely_VB on_IN having_VBG someone_NN to_TO (_( 1_LS )_) listen_VB to_TO them_PRP ,_, (_( 2_LS )_)
          accompany_VB them_PRP to_TO the_DT physician_NN ,_, (_( 3_LS )_) show_NN affection_NN to_TO
          them_PRP ,_, (_( 4_LS )_) give_VB them_PRP information_NN ,_, (_( 5_LS )_) provide_VB them_PRP with_IN
          advice_NN that_IN they_PRP would_MD want_VB ,_, (_( 6_CD )_) do_VBP things_NNS with_IN them_PRP to_TO
          turn_VB their_PRP$ minds_NNS to_TO other_JJ things_NNS ,_, (_( 7_CD )_) help_VB with_IN chores_NNS ,_,
          (_( 8_CD )_) share_NN worries_NNS and_CC fears_NNS with_IN ,_, and_CC (_( 9_CD )_) do_VBP enjoyable_JJ
          things_NNS with_IN ._. Responses_NNS to_TO each_DT question_NN were_VBD recorded_VBN on_IN
          a_DT Likert_NNP scale_NN (_( 1_CD =_SYM none_NN ,_, 2_CD =_SYM a_DT little_JJ ,_, 3_CD =_SYM some_DT ,_, 4_CD =_SYM most_JJS ,_, or_CC
          5_CD =_SYM all_DT of_IN the_DT time_NN )_) ._.
          Electronic_NNP monitoring_VBG vials_NNS were_VBD dispensed_VBD with_IN a_DT
          fresh_JJ supply_NN of_IN antihypertensive_JJ medication_NN upon_IN
          enrollment_NN in_IN the_DT study_NN ._. Participants_NNS were_VBD instructed_VBN by_IN
          pharmacists_NNS to_TO keep_VB all_DT their_PRP$ medication_NN in_IN the_DT
          monitoring_VBG vial_NN ,_, use_NN no_DT other_JJ source_NN of_IN antihypertensive_JJ
          medication_NN ,_, and_CC to_TO remove_VB only_RB one_CD dose_NN at_IN a_DT time_NN from_IN
          the_DT monitoring_VBG vial_NN ._. Participants_NNS were_VBD informed_VBN of_IN the_DT
          purpose_NN of_IN the_DT electronic_JJ medication_NN monitor_NN ._.
          Dosing_NNP events_NNS were_VBD recorded_VBN for_IN approximately_RB three_CD
          months_NNS using_VBG the_DT Medication_NNP Event_NNP Monitoring_NN System-_NNP 4_CD
          (_( MEMS-_NNP 4_LS )_) ,_, manufactured_VBN by_IN APREX_NNP Corporation_NNP ,_, Union_NNP City_NNP ,_,
          CA_NNP ._. MEMS-_NNP 4_CD is_VBZ a_DT microelectronic_JJ device_NN housed_VBN within_IN a_DT
          medication_NN bottle_NN cap_NN that_IN records_VBZ the_DT date_NN and_CC time_NN of_IN
          each_DT opening_NN ._. The_DT device_NN blocks_NNS repeated_VBD openings_NNS that_WDT
          occur_VBP within_IN 15_CD minutes_NNS of_IN each_DT other_JJ to_TO prevent_VB
          artifactual_NN inflation_NN of_IN the_DT number_NN of_IN dosing_VBG events_NNS ._.
          Data_NNP were_VBD downloaded_JJ from_IN the_DT cap_NN to_TO a_DT personal_JJ computer_NN
          using_VBG a_DT manufacturer-supplied_JJ communicator_NN and_CC
          software_NN ._.
          Two_CD to_TO three_CD weeks_NNS after_IN completion_NN of_IN electronic_JJ
          monitoring_NN ,_, a_DT followup_NN questionnaire_NN was_VBD sent_VBN to_TO
          participants_NNS to_TO update_VB information_NN on_IN their_PRP$ socioeconomic_JJ
          status_NN ,_, prescribed_VBN antihypertensive_JJ therapy_NN ,_,
          self-reported_JJ adherence_NN during_IN the_DT monitoring_VBG period_NN ,_, and_CC
          health_NN beliefs_NNS ._. Responses_NNS were_VBD once_RB again_RB obtained_VBN by_IN
          telephone_NN ._. All_DT aspects_NNS of_IN the_DT study_NN protocol_NN were_VBD
          reviewed_VBN and_CC approved_VBN by_IN the_DT Human_NNP Studies_NNP Committee_NNP of_IN
          Harvard_NNP Pilgrim_NNP Health_NNP Care_NNP ._.
        
        
          Data_NNP analysis_NN
          Due_JJ to_TO the_DT highly_RB skewed_VBN distribution_NN of_IN questionnaire_NN
          responses_NNS (_( only_RB 4_CD ._. 5_CD %_NN of_IN participants_NNS reported_VBD missing_VBG
          doses_NNS 2_CD or_CC more_JJR days_NNS per_IN week_NN )_) ,_, the_DT average_JJ number_NN of_IN
          days_NNS in_IN a_DT week_NN when_WRB participants_NNS missed_VBD a_DT dose_NN of_IN
          antihypertensive_JJ medication_NN was_VBD dichotomized_JJ at_IN 0_CD versus_CC
          ≥_NN 1_CD day_NN per_IN week_NN ._. Setting_VBG the_DT breakpoint_NN between_IN adherent_NN
          and_CC nonadherent_NN days_NNS at_IN one_CD day_NN per_IN week_NN represents_VBZ a_DT
          frequency_NN of_IN missed-dose_JJ days_NNS of_IN 14_CD ._. 3_LS %_NN (_( 1_CD /_NN 7_CD )_) ._. MEMS-_NNP 4_CD
          records_NNS were_VBD used_VBN to_TO derive_VB the_DT actual_JJ frequency_NN of_IN days_NNS
          when_WRB 1_CD or_CC more_JJR doses_NNS of_IN antihypertensive_JJ medication_NN were_VBD
          omitted_VBN ._. Adherence_NNP was_VBD defined_VBN to_TO be_VB over-estimated_JJ by_IN
          the_DT patient_NN if_IN they_PRP reported_VBD an_DT average_JJ frequency_NN of_IN
          nonadherence_NN of_IN <_NN 1_CD day_NN per_IN week_NN (_( i_NNP ._. e_SYM ._. <_NN 14_CD ._. 3_LS %_NN )_) while_IN
          electronic_JJ monitoring_NN indicated_VBN a_DT higher_JJR frequency_NN of_IN
          days_NNS with_IN missed_VBD doses_NNS (_( i_NNP ._. e_SYM ._. ≥_NN 14_CD ._. 3_LS %_NN )_) ._.
          Data_NNP analysis_NN proceeded_VBD from_IN an_DT assessment_NN of_IN crude_NN
          (_( unadjusted_JJ )_) associations_NNS with_IN over-reporting_JJ of_IN
          adherence_NN to_TO step-wise_JJ logistic_JJ regression_NN to_TO identify_VB
          which_WDT associations_NNS remained_VBD after_IN adjustment_NN for_IN other_JJ
          potential_JJ risk_NN factors_NNS ._. Six_CD categories_NNS of_IN variables_NNS were_VBD
          considered_VBN :_: (_( 1_LS )_) socioeconomic_JJ and_CC demographic_JJ background_NN
          (_( age_NN ,_, gender_NN ,_, education_NN ,_, marital_JJ status_NN ,_, employment_NN ,_,
          income_NN )_) ;_: (_( 2_LS )_) clinical_JJ features_NNS (_( blood_NN pressure_NN ,_, duration_NN
          of_IN treatment_NN ,_, number_NN of_IN doses_NNS per_IN day_NN )_) ;_: (_( 3_LS )_) clinician_NN
          communication_NN (_( previous_JJ inquiry_NN by_IN clinician_NN regarding_VBG
          medicinal_NN adherence_NN )_) (_( 4_LS )_) health_NN beliefs_NNS (_( perceived_VBN
          effectiveness_NN of_IN treatment_NN and_CC susceptibility_NN to_TO adverse_JJ
          health_NN outcomes_NNS )_) ;_: (_( 5_LS )_) health_NN status_NN (_( SF-_NNP 36_CD indices_NNS )_) ;_: and_CC
          (_( 6_CD )_) social_JJ support_NN (_( a_DT summary_NN score_NN derived_VBN from_IN the_DT
          9_CD -_: item_NN support_NN inventory_NN )_) ._. These_DT variables_NNS were_VBD chosen_VBN
          either_CC because_IN their_PRP$ information_NN might_MD be_VB obtainable_JJ or_CC
          inferred_VBN by_IN practicing_VBG clinicians_NNS ,_, or_CC they_PRP had_VBD been_VBN
          evaluated_VBN in_IN previous_JJ studies_NNS of_IN adherence_NN behavior_NN [_NN 8_CD 9_CD
          19_CD 20_CD ]_NN ._. Chi-square_NNP or_CC likelihood_NN ratio_NN tests_NNS from_IN
          logistic_JJ regression_NN models_NNS were_VBD used_VBN to_TO evaluate_VB crude_NN
          associations_NNS between_IN over-reporting_JJ and_CC possible_JJ
          predictor_NN variables_NNS ._. In_IN executing_VBG the_DT stepwise_NN logistic_JJ
          regression_NN procedure_NN ,_, a_DT selection_NN criterion_NN of_IN 
          p_NN ≤_NN ._. 2_CD was_VBD selected_VBN to_TO allow_VB for_IN
          the_DT evaluation_NN of_IN the_DT joint_JJ effect_NN of_IN multiple_JJ variables_NNS ._.
          The_DT rejection_NN criterion_NN was_VBD also_RB set_VBN relatively_RB high_JJ at_IN 
          p_NN ≥_NN ._. 1_CD to_TO permit_VB identification_NN of_IN
          all_DT potential_JJ associations_NNS with_IN over-reporting_JJ of_IN
          adherence_NN ._. As_IN described_VBD later_RB in_IN this_DT paper_NN ,_, all_DT
          variables_NNS that_WDT were_VBD ultimately_RB retained_VBN in_IN the_DT final_JJ
          logistic_JJ regression_NN model_NN amply_RB met_VBD these_DT retention_NN
          criteria_NNS ._. All_DT data_NNS manipulations_NNS and_CC statistical_JJ analyses_NNS
          were_VBD conducted_VBN using_VBG SAS_NNP ,_, release_NN 6_CD ._. 12_CD (_( SAS_NNP Institute_NNP ,_,
          Carey_NNP ,_, NC_NNP )_) ._.
        
      
      
        Results_NNS
        The_DT study_NN population_NN was_VBD composed_VBN of_IN 286_CD individuals_NNS
        whose_WP$ mean_VB age_NN was_VBD 55_CD years_NNS (_( range_NN :_: 18_CD -_: 84_CD years_NNS )_) ._. As_IN listed_VBN
        in_IN the_DT Table_NNP 1_CD ,_, approximately_RB half_NN were_VBD female_JJ ,_, one_CD third_JJ
        Black_NNP ,_, and_CC two_CD thirds_NNS had_VBD some_DT college_NN or_CC graduate_NN level_NN
        education_NN ._. The_DT mean_NN (_( ±_NN standard_JJ deviation_NN )_) systolic_JJ and_CC
        diastolic_JJ blood_NN pressures_NNS in_IN the_DT previous_JJ year_NN were_VBD 140_CD ._. 0_CD (_( ±_NN
        16_CD ._. 1_LS )_) /_NN 86_CD ._. 3_LS (_( ±_NN 10_CD ._. 4_LS )_) ._. Angiotensin_NNP converting_VBG enzyme_NN
        inhibitors_NNS were_VBD the_DT most_RBS commonly_RB prescribed_VBN
        antihypertensive_JJ agents_NNS (_( 48_CD %_NN )_) followed_VBN by_IN calcium_NN
        antagonists_NNS (_( 22_CD %_NN )_) ,_, diuretics_NNS (_( 16_CD %_NN )_) ,_, beta_NN blockers_NNS (_( 13_CD %_NN )_) ,_,
        and_CC other_JJ agents_NNS (_( 1_CD %_NN )_) ._. The_DT median_JJ duration_NN of_IN
        antihypertensive_JJ therapy_NN prior_RB to_TO involvement_NN in_IN the_DT study_NN
        was_VBD slightly_RB greater_JJR than_IN four_CD years_NNS ._.
        Average_JJ nonadherence_NN was_VBD 16_CD %_NN among_IN individuals_NNS who_WP
        reported_VBD that_IN they_PRP were_VBD nonadherent_NN <_NN 1_CD day_NN a_DT week_NN
        compared_VBN with_IN 40_CD %_NN among_IN individuals_NNS who_WP reported_VBD more_RBR
        frequent_JJ nonadherence_NN ._. The_DT Spearman_NNP correlation_NN between_IN
        reported_VBD and_CC electronically_RB measured_VBN adherence_NN was_VBD 0_CD ._. 34_CD (_( 
        p_NN -_: value_NN =_SYM ._. 0001_CD )_) ._. While_IN only_RB 21_CD %_NN of_IN
        participants_NNS acknowledged_VBD missing_VBG doses_NNS one_CD or_CC more_JJR days_NNS
        per_IN week_NN ,_, electronic_JJ medication_NN monitoring_VBG documented_VBN
        nonadherence_NN at_IN this_DT or_CC greater_JJR levels_NNS in_IN 42_CD %_NN of_IN
        participants_NNS ._. Seventy-eight_NNP (_( 27_CD %_NN )_) of_IN the_DT 286_CD participants_NNS
        over-reported_JJ their_PRP$ actual_JJ adherence_NN ._. As_IN shown_VBN in_IN Table_NNP 1_CD ,_,
        being_VBG unmarried_JJ (_( which_WDT included_VBD being_VBG widowed_VBN ,_, separated_JJ ,_,
        divorced_VBN ,_, or_CC never_RB married_VBN ;_: OR_NNP =_SYM 1_CD ._. 80_CD ;_: 95_CD %_NN CI_NNP =_SYM 1_CD ._. 06_CD -_: 3_CD ._. 06_CD ;_: 
        p_NN =_SYM ._. 03_CD )_) ,_, annual_JJ income_NN of_IN <_NN $_$ 15_CD ,_, 000_CD
        relative_JJ to_TO >_NN $_$ 30_CD ,_, 000_CD (_( OR_NNP =_SYM 2_CD ._. 66_CD ;_: 95_CD %_NN CI_NNP =_SYM 1_CD ._. 16_CD -_: 6_CD ._. 09_CD ;_: 
        p_NN =_SYM ._. 02_CD )_) ,_, prescription_NN of_IN >_NN 1_CD dose_NN
        per_IN day_NN (_( OR_NNP =_SYM 2_CD ._. 66_CD 95_CD %_NN CI_NNP =_SYM 1_CD ._. 57_CD -_: 4_CD ._. 51_CD ;_: 
        p_NN =_SYM ._. 0003_CD )_) ,_, and_CC diminished_VBD perceived_VBN
        risk_NN from_IN nonadherence_NN (_( OR_NNP =_SYM 1_CD ._. 28_CD for_IN a_DT 1_CD -_: level_NN difference_NN ;_:
        95_CD %_NN CI_NNP =_SYM 1_CD ._. 06_CD -_: 1_CD ._. 55_CD ;_: 
        p_NN =_SYM ._. 01_CD )_) were_VBD associated_VBN with_IN
        over-reporting_JJ of_IN adherence_NN in_IN unadjusted_JJ analyses_NNS ._.
        Step-wise_NNP logistic_JJ regression_NN selected_VBN and_CC retained_VBN
        being_VBG prescribed_VBN >_NN 1_CD dose_NN per_IN day_NN (_( OR_NNP =_SYM 2_CD ._. 58_CD ;_: 95_CD %_NN CI_NNP =_SYM
        1_CD ._. 50_CD -_: 4_CD ._. 41_CD ;_: 
        p_NN =_SYM ._. 0006_CD )_) ,_, diminished_VBN health_NN risk_NN
        perception_NN (_( OR_NNP =_SYM 1_CD ._. 35_CD ;_: 95_CD %_NN CI_NNP =_SYM 1_CD ._. 10_CD -_: 1_CD ._. 64_CD ;_: 
        p_NN =_SYM ._. 0035_CD )_) ,_, and_CC annual_JJ income_NN of_IN
        <_NN $_$ 15_CD ,_, 000_CD (_( OR_NNP =_SYM 2_CD ._. 64_CD ;_: 95_CD %_NN CI_NNP =_SYM 1_CD ._. 13_CD -_: 6_CD ._. 18_CD ;_: 
        p_NN =_SYM ._. 025_CD )_) in_IN that_DT order_NN ._. Lower_JJR mean_NN
        systolic_JJ blood_NN pressure_NN in_IN the_DT year_NN prior_RB to_TO participation_NN
        in_IN the_DT study_NN was_VBD initially_RB selected_VBN (_( p_NN =_SYM ._. 12_CD )_) but_CC not_RB
        retained_VBD in_IN the_DT final_JJ regression_NN model_NN ._. Marital_NNP status_NN was_VBD
        not_RB chosen_VBN by_IN the_DT step-wise_JJ procedure_NN ._. Age_NNP ,_, gender_NN ,_, and_CC
        race_NN /_NN ethnicity_NN also_RB were_VBD not_RB associated_VBN (_( p_NN >_NN ._. 05_CD )_) with_IN
        over-reporting_JJ in_IN both_DT the_DT crude_NN and_CC step-wise_JJ logistic_JJ
        regression_NN analyses_NNS ._. Including_VBG all_DT variables_NNS with_IN crude_NN
        associations_NNS (_( p_NN ≤_NN ._. 1_LS )_) with_IN over-reporting_JJ of_IN adherence_NN
        (_( marital_JJ status_NN ,_, income_NN ,_, mean_VB diastolic_JJ blood_NN pressure_NN in_IN
        the_DT previous_JJ year_NN ,_, number_NN of_IN daily_JJ doses_NNS ,_, and_CC perceived_VBD
        risk_NN )_) in_IN a_DT single_JJ logistic_JJ regression_NN model_NN did_VBD not_RB
        materially_RB affect_VB our_PRP$ findings_NNS (_( results_NNS not_RB shown_VBN )_) ._. The_DT
        link_NN between_IN >_NN 1_CD daily_JJ dose_NN and_CC over-reporting_JJ of_IN
        adherence_NN was_VBD blocked_VBN (_( OR_NNP =_SYM 1_CD ._. 38_CD ;_: 95_CD %_NN CI_NNP =_SYM 0_CD ._. 73_CD -_: 2_CD ._. 64_CD ;_: 
        p_NN =_SYM ._. 33_CD )_) by_IN adjusting_VBG for_IN actual_JJ
        adherence_NN as_IN measured_VBN by_IN MEMS-_NNP 4_CD in_IN the_DT final_JJ ,_, selected_VBN
        model_NN indicating_VBG that_IN the_DT association_NN between_IN dosing_VBG
        frequency_NN and_CC over-reporting_JJ was_VBD most_RBS likely_JJ mediated_JJ by_IN
        actual_JJ adherence_NN ._.
      
      
        Discussion_NNP
        The_DT main_JJ purpose_NN of_IN this_DT exploratory_JJ analysis_NN was_VBD to_TO
        identify_VB potential_JJ risk_NN factors_NNS for_IN over-reporting_JJ of_IN
        adherence_NN ._. We_PRP observed_VBD that_IN frequent_JJ daily_JJ dosing_VBG ,_, reduced_VBN
        risk_NN perception_NN from_IN nonadherence_NN ,_, and_CC lower_JJR annual_JJ income_NN
        were_VBD associated_VBN with_IN over-reporting_JJ in_IN our_PRP$ study_NN
        population_NN ._. Not_RB surprisingly_RB ,_, less_JJR adherent_NN individuals_NNS
        were_VBD also_RB more_RBR likely_JJ to_TO over-report_JJ their_PRP$ adherence_NN than_IN
        other_JJ more_JJR adherent_NN individuals_NNS ,_, a_DT pattern_NN that_WDT has_VBZ been_VBN
        reported_VBN by_IN other_JJ investigators_NNS [_NN 8_CD 12_CD ]_NN ._.
        The_DT exploratory_JJ nature_NN of_IN this_DT investigation_NN makes_VBZ
        cautious_JJ interpretation_NN of_IN our_PRP$ findings_NNS necessary_JJ ._. Multiple_NNP
        comparisons_NNS were_VBD made_VBN in_IN this_DT study_NN and_CC consequently_RB the_DT
        results_NNS may_MD have_VB been_VBN chance_NN findings_NNS ._. Use_NN of_IN a_DT very_RB
        conservative_JJ standard_NN of_IN significance_NN based_VBN on_IN the_DT
        Bonferroni_NNP adjustment_NN would_MD require_VB a_DT p-value_JJ of_IN ≤_NN ._. 002_CD
        (_( ._. 05_CD /_NN 23_CD where_WRB ._. 05_CD represents_VBZ the_DT traditional_JJ standard_NN of_IN
        significance_NN and_CC 23_CD the_DT number_NN of_IN comparisons_NNS made_VBN )_) ._. By_IN
        these_DT criteria_NNS ,_, only_RB dosing_VBG frequency_NN would_MD still_RB be_VB
        considered_VBN statistically_RB significant_JJ ._.
        The_DT association_NN between_IN dosing_VBG frequency_NN and_CC
        over-reporting_JJ of_IN adherence_NN was_VBD apparently_RB mediated_JJ by_IN
        actual_JJ adherence_NN behavior_NN because_IN adjusting_VBG statistically_RB
        for_IN electronically_RB measured_VBN adherence_NN blocked_VBD this_DT
        relationship_NN ._. This_DT is_VBZ not_RB surprising_JJ because_IN frequent_JJ
        dosing_VBG usually_RB predicts_VBZ lower_JJR adherence_NN [_NN 5_CD 21_CD ]_NN and_CC lower_JJR
        adherence_NN is_VBZ associated_VBN with_IN over-reporting_JJ ._. As_IN a_DT
        consequence_NN ,_, frequent_JJ dosing_VBG would_MD be_VB expected_VBN to_TO correlate_VBP
        with_IN over-reporting_JJ via_IN its_PRP$ connection_NN with_IN actual_JJ
        adherence_NN ._.
        On_IN a_DT more_JJR conjectural_NN level_NN ,_, the_DT observed_VBN connection_NN
        between_IN decreased_VBD perception_NN of_IN health_NN risk_NN from_IN
        nonadherence_NN and_CC over-reporting_JJ of_IN adherence_NN may_MD indicate_VB
        that_DT health_NN belief_NN models_NNS that_WDT posit_NN a_DT direct_JJ relationship_NN
        between_IN perceived_VBN risk_NN and_CC adherence_NN may_MD also_RB apply_VB to_TO the_DT
        accurate_JJ recollection_NN of_IN past_JJ medication_NN use_NN [_NN 22_CD 23_CD 24_CD 25_CD
        ]_NN ._. In_IN addition_NN ,_, the_DT association_NN with_IN lower_JJR household_NN
        income_NN in_IN our_PRP$ study_NN population_NN may_MD indicate_VB that_IN a_DT more_RBR
        stressful_JJ if_IN not_RB disorganized_JJ life_NN situation_NN ,_, as_IN suggested_VBN
        by_IN lower_JJR socioeconomic_JJ status_NN ,_, may_MD increase_VB the_DT likelihood_NN
        of_IN inaccurately_RB believing_VBG that_WDT missed_VBD doses_NNS were_VBD taken_VBN ._.
        Furthermore_RB ,_, some_DT individuals_NNS may_MD report_VB what_WP they_PRP believe_VBP
        that_IN clinicians_NNS or_CC researchers_NNS want_VBP to_TO hear_VB ._. This_DT behavior_NN
        might_MD be_VB more_RBR likely_JJ when_WRB the_DT perceived_VBN difference_NN in_IN power_NN
        (_( as_IN measured_VBN by_IN wealth_NN and_CC income_NN )_) is_VBZ maximal_NN ._.
        Several_JJ factors_NNS that_WDT may_MD contribute_VB to_TO the_DT inaccurate_JJ
        recounting_VBG of_IN adherence_NN by_IN patients_NNS were_VBD not_RB evaluated_VBN in_IN
        this_DT study_NN ._. The_DT research_NN instruments_NNS did_VBD not_RB cover_VB
        participants_NNS '_POS attitudes_NNS towards_IN the_DT healthcare_NN system_NN ,_,
        their_PRP$ healthcare_NN providers_NNS ,_, or_CC the_DT research_NN staff_NN involved_VBN
        in_IN this_DT study_NN ._. The_DT quality_NN of_IN the_DT patient-physician_JJ (_( and_CC by_IN
        extension_NN the_DT participant-researcher_JJ )_) relationship_NN may_MD have_VB
        a_DT significant_JJ impact_NN on_IN what_WP patients_NNS will_MD discuss_VB with_IN
        their_PRP$ healthcare_NN provider_NN [_NN 26_CD ]_NN ._. Furthermore_RB ,_, formal_JJ
        psychological_JJ and_CC cognitive_JJ testing_NN were_VBD not_RB performed_VBN on_IN
        study_NN participants_NNS to_TO permit_VB evaluation_NN of_IN the_DT effect_NN of_IN
        memory_NN ,_, judgement_NN ,_, mood_NN ,_, and_CC personality_NN on_IN adherence_NN and_CC
        the_DT accurate_JJ reporting_NN of_IN noncompliance_NN ._.
      
      
        Conclusions_NNP
        This_DT investigation_NN is_VBZ one_CD of_IN the_DT first_JJ to_TO evaluate_VB
        possible_JJ risk_NN factors_NNS for_IN over-reporting_JJ of_IN adherence_NN by_IN
        patients_NNS ._. The_DT findings_NNS suggest_VBP that_IN factors_NNS related_VBN to_TO
        socioeconomic_JJ status_NN ,_, the_DT dosing_VBG regimen_NN ,_, and_CC perceived_VBD
        risk_NN from_IN nonadherence_NN may_MD influence_VB how_WRB accurately_RB
        patients_NNS recall_VBP and_CC report_VB their_PRP$ adherence_NN ._. Additional_JJ
        investigation_NN will_MD be_VB needed_VBN to_TO confirm_VB and_CC extend_VB these_DT
        findings_NNS as_RB well_RB as_IN elucidate_NN the_DT possible_JJ underlying_VBG
        behavioral_JJ mechanisms_NNS that_WDT are_VBP involved_VBN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
